LakeShore Biopharma Co (LakeShore Biopharma Co) EV-to-EBIT : -5.34 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LakeShore Biopharma Co's Enterprise Value is $208.96 Mil. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.13 Mil. Therefore, LakeShore Biopharma Co's EV-to-EBIT for today is -5.34.

The historical rank and industry rank for LakeShore Biopharma Co's EV-to-EBIT or its related term are showing as below:

LSB' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.41 Med: -5.99 Max: -3.22
Current: -5.34

During the past 3 years, the highest EV-to-EBIT of LakeShore Biopharma Co was -3.22. The lowest was -61.41. And the median was -5.99.

LSB's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs LSB: -5.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. LakeShore Biopharma Co's Enterprise Value for the quarter that ended in Sep. 2023 was $114.77 Mil. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.13 Mil. LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -34.09%.

LakeShore Biopharma Co EV-to-EBIT Historical Data

The historical data trend for LakeShore Biopharma Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co EV-to-EBIT Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

EV-to-EBIT

-10.17

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-10.17	-

Competitive Comparison of LakeShore Biopharma Co's EV-to-EBIT

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBIT falls into.

LakeShore Biopharma Co EV-to-EBIT Calculation

LakeShore Biopharma Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	208.961	/	-39.126
	=	-5.34

LakeShore Biopharma Co's current Enterprise Value is $208.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.13 Mil.

LakeShore Biopharma Co (NAS:LSB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-39.126	/	114.77156
	=	-34.09 %

LakeShore Biopharma Co's Enterprise Value for the quarter that ended in Sep. 2023 was $114.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.13 Mil.

LakeShore Biopharma Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.